Novartis collaborates with Incyte with initiation plan of clinical study of Jakavi in COVID-19 patients Medical Dialogues Bureau6 April 2020 9:54 AMBasel: Novartis has announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib)...
Novartis CEO says Malaria drug is biggest hope against coronavirus - SonntagsZeitung Medical Dialogues Bureau30 March 2020 7:49 AMZurich: Novartis Chief Executive Vas Narasimhan said his Sandoz generics unit's malaria, lupus and arthritis drug hydroxychloroquine is the company's...
Novartis, Life sciences companies commit to fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation Medical Dialogues Bureau29 March 2020 6:49 AMBasel: Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture, and...
Novartis to donate up to 130 million doses of hydroxychloroquine for COVID-19 Medical Dialogues Bureau24 March 2020 4:30 AMBasel: Novartis has announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic...
Novartis receives Japanese approval for Zolgensma for spinal muscular atrophy Medical Dialogues Bureau22 March 2020 6:15 AMZolgensma is a one-time gene therapy designed to address the genetic root cause of the disease by replacing the function of the missing or nonworking...
Novartis updates on uses and safety of Beovu in patients with wet AMD Medical Dialogues Bureau3 March 2020 4:30 AMIf clinical signs of intraocular inflammation or changes in vision after Beovu injection are observed doctor should perform the appropriate diagnostic...
Novartis announces FDA and EMA filing acceptance of ofatumumab, for treatment of relapsing form of MS Medical Dialogues Bureau25 Feb 2020 7:33 AM"With ofatumumab, we underpin our relentless dedication to reimagining medicine for patients across the MS spectrum and will work closely with the...
Top Cos in pharmaceutical supply chain develop Blockchain system to track prescription drugs, stop counterfeit Medical Dialogues Bureau22 Feb 2020 10:34 AMAmong the 24 participating companies are Amgen Inc, FedEx Corp, GlaxoSmithKline Plc, Novartis, AmerisourceBergen Corp , Sanofi ), Walgreens Boots...
Novartis cancer therapy MET inhibitor capmatinib granted USFDA priority review Medical Dialogues Bureau13 Feb 2020 4:15 AMCapmatinib (INC280) is an investigational, oral, potent and selective MET inhibitor licensed to Novartis by Incyte Corporation in 2009. Under the...
Novartis blockbuster Mayzent wins European nod for multiple sclerosis Medical Dialogues Bureau22 Jan 2020 5:55 AM The European marketing authorization makes Mayzent the first and only indicated oral treatment proven in SPMS patients with the active disease based...
Zydus Cadila unveils affordable anti-diabetic drug Vildagliptin under brands Vinglyn, Vinglyn M Medical Dialogues Bureau12 Dec 2019 6:23 AMAhmedabad: With the Novartis Blockbuster Vildagliptin going off patent, Zydus Cadila has taken made its move towards affordable diabetes care in India...
Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list Medical Dialogues Bureau29 Nov 2019 3:45 AMSeventy new drugs such as Roche's breast cancer treatment Pertuzumab, sold under the trade name Perjeta, Novartis's dermatitis treatment Omalizumab,...
